NBTXR3 Archives | Be Korea-savvy

Home / Posts tagged NBTXR3

Nanobiotix Announces Publication of Phase III Soft Tissue Sarcoma Data for First-in-class NBTXR3 in the Lancet Oncology

Paris, France and Cambridge, Massachusetts, USA, Jul. 9 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the previously reported results from the Phase II/III Act.In.Sarc trial evaluating NBTXR3 in patients with advanced STS have been published online in The [...]

NANOBIOTIX: Positive Phase II/III Results for NBTXR3 in Soft Tissue Sarcoma Presented at ESMO

Paris, France, and Cambridge, Massachusetts (USA), Oct. 19 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, presented NBTXR3 positive Phase II/III Act.in.sarc results in patients with locally advanced Soft Tissue Sarcoma at the European Society for Medical Oncology (ESMO) 2018 Congress [...]

Nanobiotix Receives First Tranche Disbursement of 16 Million Euros Financing from European Investment Bank

Paris, France and Cambridge, Massachusetts, Oct. 16 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that the Company received an initial 16 million euros as the first disbursement under the previously announced non-dilutive loan from the European Investment Bank [...]

Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other Program Data Presented at ImmunoRad 2018

PARIS / CAMBRIDGE, Mass., Sept. 20 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces it will present an update on and data from its NBTXR3 development program at the International Conference on Immunotherapy Radiotherapy Combinations that will take place from [...]